TY - JOUR AU - Ross, J. S. AU - Fletcher, J. A. AU - Linette, G. P. PY - 2003 DA - 2003// TI - The her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy JO - Oncologist VL - 8 UR - https://doi.org/10.1634/theoncologist.8-4-307 DO - 10.1634/theoncologist.8-4-307 ID - Ross2003 ER - TY - JOUR AU - Pegram, M. D. AU - Konecny, G. AU - Slamon, D. J. PY - 2000 DA - 2000// TI - The molecular and cellular biology of HER2/neu gene amplification/over-expression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer JO - Cancer Treat Res VL - 103 UR - https://doi.org/10.1007/978-1-4757-3147-7_4 DO - 10.1007/978-1-4757-3147-7_4 ID - Pegram2000 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Perez, E. A. AU - Romond, E. H. AU - Suman, V. J. PY - 2011 DA - 2011// TI - Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.35.0868 DO - 10.1200/JCO.2011.35.0868 ID - Perez2011 ER - TY - JOUR AU - Gianni, L. AU - Dafni, U. AU - Gelber, R. D. PY - 2011 DA - 2011// TI - Herceptin adjuvant (HERA) trial study team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70033-X DO - 10.1016/S1470-2045(11)70033-X ID - Gianni2011 ER - TY - JOUR AU - Dent, S. AU - Oyan, B. AU - Honig, A. PY - 2013 DA - 2013// TI - HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials JO - Cancer Treat Rev VL - 39 UR - https://doi.org/10.1016/j.ctrv.2013.01.002 DO - 10.1016/j.ctrv.2013.01.002 ID - Dent2013 ER - TY - JOUR AU - Amiri-Kordestani, L. AU - Wedam, S. AU - Zhang, L. PY - 2014 DA - 2014// TI - First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-1268 DO - 10.1158/1078-0432.CCR-14-1268 ID - Amiri-Kordestani2014 ER - TY - JOUR AU - Hicks, D. G. AU - Kulkarni, S. PY - 2008 DA - 2008// TI - HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools JO - Am J Clin Pathol VL - 129 UR - https://doi.org/10.1309/99AE032R9FM8WND1 DO - 10.1309/99AE032R9FM8WND1 ID - Hicks2008 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Schwartz, J. N. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.2775 DO - 10.1200/JCO.2006.09.2775 ID - Wolff2007 ER - TY - JOUR AU - Hicks, D. G. AU - Kulkarni, S. PY - 2008 DA - 2008// TI - Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing JO - Arch Pathol Lab Med VL - 132 ID - Hicks2008 ER - TY - JOUR AU - Baselga, J. AU - Cortés, J. AU - Kim, S. B. PY - 2012 DA - 2012// TI - CLEOPATRA study group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113216 DO - 10.1056/NEJMoa1113216 ID - Baselga2012 ER - TY - JOUR AU - Verma, S. AU - Miles, D. AU - Gianni, L. PY - 2012 DA - 2012// TI - EMILIA study group. Trastuzumab emtansine for HER2-positive advanced breast cancer JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1209124 DO - 10.1056/NEJMoa1209124 ID - Verma2012 ER - TY - JOUR AU - Hurvitz, S. A. AU - Dirix, L. AU - Kocsis, J. PY - 2013 DA - 2013// TI - Phase II randomized study of Trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.9694 DO - 10.1200/JCO.2012.44.9694 ID - Hurvitz2013 ER - TY - JOUR AU - Hicks, D. G. AU - Whitney-Miller, C. PY - 2011 DA - 2011// TI - HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge JO - Appl Immunohistochem Mol Morphol VL - 19 UR - https://doi.org/10.1097/PAI.0b013e31822c3a0f DO - 10.1097/PAI.0b013e31822c3a0f ID - Hicks2011 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Hicks, D. G. PY - 2013 DA - 2013// TI - American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline update JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.50.9984 DO - 10.1200/JCO.2013.50.9984 ID - Wolff2013 ER - TY - JOUR AU - Scaltriti, M. AU - Nuciforo, P. AU - Bradbury, I. PY - 2015 DA - 2015// TI - High HER2 expression correlates with response to the combination of lapatinib and trastuzumab JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1824 DO - 10.1158/1078-0432.CCR-14-1824 ID - Scaltriti2015 ER - TY - JOUR AU - Goldstein, N. S. AU - Hewitt, S. M. AU - Taylor, C. R. PY - 2007 DA - 2007// TI - Members of ad-hoc committee on immunohistochemistry standardization. Recommendations for improved standardization of immunohistochemistry JO - Appl Immunohistochem Mol Morphol VL - 15 UR - https://doi.org/10.1097/PAI.0b013e31804c7283 DO - 10.1097/PAI.0b013e31804c7283 ID - Goldstein2007 ER - TY - JOUR AU - Hicks, D. G. AU - Tubbs, R. R. PY - 2005 DA - 2005// TI - Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines JO - Hum Pathol VL - 36 UR - https://doi.org/10.1016/j.humpath.2004.11.010 DO - 10.1016/j.humpath.2004.11.010 ID - Hicks2005 ER - TY - JOUR AU - Harigopal, M. AU - Barlow, W. E. AU - Tedeschi, G. PY - 2010 DA - 2010// TI - Multiplexed assessment of the southwest oncology group-directed intergroup breast Cancer trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome JO - Am J Pathol VL - 176 UR - https://doi.org/10.2353/ajpath.2010.090711 DO - 10.2353/ajpath.2010.090711 ID - Harigopal2010 ER - TY - JOUR AU - Huang, W. AU - Reinholz, M. AU - Weidler, J. PY - 2010 DA - 2010// TI - Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay JO - Am J Clin Pathol VL - 134 UR - https://doi.org/10.1309/AJCP3BZY4YAFNTRG DO - 10.1309/AJCP3BZY4YAFNTRG ID - Huang2010 ER - TY - STD TI - Larson JS, Goodman LJ, Tan Y, et al. Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark) for the measurement of HER2 Total protein and HER2 homodimers in FFPE breast Cancer tumor specimens. Patholog Res Int. 2010;814176. ID - ref21 ER - TY - JOUR AU - Lequin, R. M. PY - 2005 DA - 2005// TI - Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA) JO - Clin Chem VL - 51 UR - https://doi.org/10.1373/clinchem.2005.051532 DO - 10.1373/clinchem.2005.051532 ID - Lequin2005 ER - TY - JOUR AU - Weemen, B. K. AU - Schuurs, A. H. PY - 1971 DA - 1971// TI - Immunoassay using antigen-enzyme conjugates JO - FEBS Lett VL - 15 UR - https://doi.org/10.1016/0014-5793(71)80319-8 DO - 10.1016/0014-5793(71)80319-8 ID - Weemen1971 ER - TY - JOUR AU - Opstal-van Winden, A. W. AU - Vermeulen, R. C. AU - Peeters, P. H. PY - 2012 DA - 2012// TI - Early diagnostic protein biomarkers for breast cancer: how far have we come? JO - Breast Cancer Res Treat VL - 134 UR - https://doi.org/10.1007/s10549-011-1907-2 DO - 10.1007/s10549-011-1907-2 ID - Opstal-van Winden2012 ER - TY - JOUR AU - Lavabre-Bertrand, T. AU - Janossy, G. AU - Ivory, K. PY - 1994 DA - 1994// TI - Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression JO - Cytometry VL - 18 UR - https://doi.org/10.1002/cyto.990180404 DO - 10.1002/cyto.990180404 ID - Lavabre-Bertrand1994 ER - TY - JOUR AU - Gonda, K. AU - Watanabe, M. AU - Tada, H. PY - 2017 DA - 2017// TI - Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-06534-z DO - 10.1038/s41598-017-06534-z ID - Gonda2017 ER - TY - JOUR AU - Jorgensen, J. T. AU - Møller, S. AU - Rasmussen, B. B. PY - 2011 DA - 2011// TI - High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 ISH pharmDx kit JO - Am J Clin Pathol VL - 136 UR - https://doi.org/10.1309/AJCPJPJ8ZWGDTTWC DO - 10.1309/AJCPJPJ8ZWGDTTWC ID - Jorgensen2011 ER - TY - JOUR AU - Symmans, W. F. AU - Peintinger, F. AU - Hatzis, C. PY - 2007 DA - 2007// TI - Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.10.6823 DO - 10.1200/JCO.2007.10.6823 ID - Symmans2007 ER - TY - JOUR AU - Symmans, W. F. AU - Wei, C. AU - Gould, R. PY - 2017 DA - 2017// TI - Long-term prognostic risk after neoadjuvant chemotherapy associated with residual Cancer burden and breast Cancer subtype JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2015.63.1010 DO - 10.1200/JCO.2015.63.1010 ID - Symmans2017 ER - TY - JOUR AU - Jensen, K. AU - Krusenstjerna-Hafstrøm, R. AU - Lohse, J. PY - 2017 DA - 2017// TI - A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2 JO - Mod Pathol VL - 30 UR - https://doi.org/10.1038/modpathol.2016.176 DO - 10.1038/modpathol.2016.176 ID - Jensen2017 ER - TY - JOUR AU - Downs-Kelly, E. AU - Yoder, B. J. AU - Stoler, M. PY - 2005 DA - 2005// TI - The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study JO - Am J Surg Pathol VL - 29 UR - https://doi.org/10.1097/01.pas.0000165528.78945.95 DO - 10.1097/01.pas.0000165528.78945.95 ID - Downs-Kelly2005 ER - TY - JOUR AU - Pauletti, G. AU - Godolphin, W. AU - Press, M. F. PY - 1996 DA - 1996// TI - Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization JO - Oncogene VL - 13 ID - Pauletti1996 ER - TY - JOUR AU - Lipton, A. AU - Köstler, W. J. AU - Leitzel, K. PY - 2010 DA - 2010// TI - Trastuzumab response biomarker group. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.25430 DO - 10.1002/cncr.25430 ID - Lipton2010 ER - TY - JOUR AU - Benz, C. C. AU - O'Hagan, R. C. AU - Richter, B. PY - 1997 DA - 1997// TI - HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer JO - Oncogene VL - 15 UR - https://doi.org/10.1038/sj.onc.1201331 DO - 10.1038/sj.onc.1201331 ID - Benz1997 ER - TY - JOUR AU - Wang, S. C. AU - Hung, M. C. PY - 2001 DA - 2001// TI - HER2 overexpression and cancer targeting JO - Semin Oncol VL - 28 UR - https://doi.org/10.1016/S0093-7754(01)90289-1 DO - 10.1016/S0093-7754(01)90289-1 ID - Wang2001 ER - TY - JOUR AU - Cortazar, P. AU - Zhang, L. AU - Untch, M. PY - 2014 DA - 2014// TI - Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(13)62422-8 DO - 10.1016/S0140-6736(13)62422-8 ID - Cortazar2014 ER - TY - JOUR AU - Miyashita, M. AU - Gonda, K. AU - Tada, H. PY - 2016 DA - 2016// TI - Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging JO - Cancer Med VL - 5 UR - https://doi.org/10.1002/cam4.898 DO - 10.1002/cam4.898 ID - Miyashita2016 ER - TY - JOUR AU - Nuciforo, P. AU - Thyparambil, S. AU - Aura, C. PY - 2016 DA - 2016// TI - High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy JO - Mol Oncol VL - 10 UR - https://doi.org/10.1016/j.molonc.2015.09.002 DO - 10.1016/j.molonc.2015.09.002 ID - Nuciforo2016 ER - TY - JOUR AU - Cheng, H. AU - Bai, Y. AU - Sikov, W. PY - 2014 DA - 2014// TI - Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-326 DO - 10.1186/1471-2407-14-326 ID - Cheng2014 ER - TY - JOUR AU - Bianchini, G. AU - Kiermaier, A. AU - Bianchi, G. V. PY - 2017 DA - 2017// TI - Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer JO - Breast Cancer Res VL - 19 UR - https://doi.org/10.1186/s13058-017-0806-9 DO - 10.1186/s13058-017-0806-9 ID - Bianchini2017 ER - TY - STD TI - Singer CF, Tan YY, Fitzal F, et al. Austrian Breast and Colorectal Cancer Study Group. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clin Cancer Res. 2017. ID - ref41 ER - TY - JOUR AU - Solinas, C. AU - Ceppi, M. AU - Lambertini, M. PY - 2017 DA - 2017// TI - Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials JO - Cancer Treat Rev VL - 57 UR - https://doi.org/10.1016/j.ctrv.2017.04.005 DO - 10.1016/j.ctrv.2017.04.005 ID - Solinas2017 ER - TY - JOUR AU - Lesurf, R. AU - Griffith, O. L. AU - Griffith, M. PY - 2017 DA - 2017// TI - Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx048 DO - 10.1093/annonc/mdx048 ID - Lesurf2017 ER - TY - JOUR AU - Yardley, D. A. AU - Kaufman, P. A. AU - Huang, W. PY - 2015 DA - 2015// TI - Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter collaborative biomarker study and correlation with overall survival JO - Breast Cancer Res VL - 17 UR - https://doi.org/10.1186/s13058-015-0543-x DO - 10.1186/s13058-015-0543-x ID - Yardley2015 ER -